Companies
/Healthcare
Idexx Laboratories Inc
$700.65
▼ $3.58 (−0.51%) today
Markets closed · 10:14pm ET
IDEXX Laboratories (IDXX) Earnings History & Trends
89%
EPS beat rate
+5.67%
Avg. EPS surprise
Consecutive EPS beats
IDXX vs Market · 30-day return after each reportIDXXS&P 500
IDXX EPS Trend · estimate vs actualEstimateActual
IDXX Revenue Trend · estimate vs actualEstimateActual
How Often Does IDEXX Laboratories Beat Earnings Estimates?
IDEXX Laboratories beat EPS estimates in 7 of its last 8 reported quarters, and has beaten 8 quarters in a row.
| Quarter | EPS · est. | Surprise | Revenue · est. | Surprise |
|---|---|---|---|---|
| Q3 2026 Q3 EPS included a $0.03 per share benefit from a non-operating gain on an equity investment, $0.01 per share in tax benefits from share-based compensation, and a $0.04 per share benefit from year-over-year currency changes, while absorbing acquisition impacts including transaction-related costs; company-reported comparable EPS was $3.96. | $4.01 est. $3.72 | +7.91% | $1.2B est. $1.2B | +1.83% |
| Q2 2026 | $4.27 | — | $1.2B | — |
| Q1 2026 | $3.47 est. $3.41 | +1.74% | $1.1B est. $1.1B | +2.88% |
| Q4 2025 Q4 GAAP diluted EPS includes $0.09 per share positive impact from currency changes and $0.07 per share in tax benefits from share-based compensation; company-reported non-GAAP comparable EPS was $2.92. | $3.08 est. $2.94 | +4.85% | $1.1B est. $1.1B | +1.73% |
| Q3 2025 | $3.40 est. $3.14 | +8.29% | $1.1B est. $1.1B | +3.16% |
| Q2 2025 | $3.63 est. $3.30 | +9.97% | $1.1B est. $1.1B | +3.95% |
| Q1 2025 | $2.96 est. $2.84 | +4.06% | $998.4M est. $996.5M | +0.20% |
| Q2 2023 | $2.67 est. $2.47 | +8.10% | $943.6M est. $934.4M | +0.99% |
| Q1 2022 | $2.27 est. $2.26 | +0.44% | $836.5M est. $839.7M | −0.38% |
Figures from SEC filings and company reports. Not investment advice.